Aims: To investigate the effect on risk of major adverse cardiac events (MACE) of lipid
lowering treatment with fluvastatin 80 mg/day after a first percutaneous coronary intervention …

ContextPercutaneous coronary intervention (PCI) is associated with excellent short-term
improvements in ischemic symptoms, yet only three fifths of PCI patients at 5 years and one …

BACKGROUND: In the LIPS (Lescol Intervention Prevention Study), fluvastatin 80 mg/day
reduced the risk of major adverse cardiac events (MACE) by 22% versus placebo (p= 0.01) …

The Lescol Intervention Prevention Study (LIPS) was the first randomized trial to show a
significant reduction in the risk of cardiac events in patients started on fluvastatin …

Background Experimental and clinical observations suggest that lowering serum lipid levels
may reduce the risk of restenosis after coronary angioplasty. We report the results of a …

BACKGROUND: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)
inhibit atherosclerosis and reduce both morbidity and mortality in patients with coronary …

We assessed the impact of long-term fluvastatin treatment on adverse atherosclerotic
cardiac events (cardiac death, myocardial infarction, and revascularization excluding repeat …

The primary objective of the present study was to investigate the cholesterol-lowering effect
of fluvastatin on the incidence of cardiac events in hyperlipidaemic patients with …

Background The LIPID study is a major trial of secondary prevention of coronary-heart-
disease events that includes hospital admission with unstable angina (as well as myocardial …

Abstract Background The 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase
inhibitors competitively inhibit biosynthesis of mevalonate, a precursor of non-sterol …